Search
Enlivex Therapeutics Ltd
ENLVAdd to Watchlist
1.560USD
-0.020-1.27%
Market hours （ET）Quotes delayed by 15 min
24.69MMarket Cap
0.06P/E TTM
More Details of Enlivex Therapeutics Ltd Company
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Enlivex Therapeutics Ltd Profile
Ticker SymbolENLV
Company nameEnlivex Therapeutics Ltd
IPO dateJul 30, 2014
CEOHershkovitz (Oren)
Number of employees36
Security typeOrdinary Share
Fiscal year-endJul 30
Address14 Einstein St.
CityNESS-ZIONA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code7403618
Phone97286623301
Websitehttps://www.enlivex.com/
Ticker SymbolENLV
IPO dateJul 30, 2014
CEOHershkovitz (Oren)
Company Executives of Enlivex Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Dr. Gili Hart, Ph.D.
Dr. Gili Hart, Ph.D.
Independent Director
Independent Director
481.00
+26.61%
Mr. Sangwoo Lee
Mr. Sangwoo Lee
Director
Director
--
--
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Dr. Bernhard Jurgen Kirschbaum, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Mr. Shai A. Novik
Mr. Shai A. Novik
Executive Chairman of the Board
Executive Chairman of the Board
464.93K
+87.69%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Dr. Abraham (Avri) Havron, Ph.D.
Dr. Abraham (Avri) Havron, Ph.D.
Independent Director
Independent Director
12.22K
+1.05%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
Mrs. Shachar Shlosberger, CPA
Mrs. Shachar Shlosberger, CPA
Chief Financial Officer
Chief Financial Officer
2.01K
+78.69%
FAQs
Who are the top five shareholders of Enlivex Therapeutics Ltd?
The top five shareholders of Enlivex Therapeutics Ltd are: Mr. Shai A. Novik
How many institutions hold shares of Enlivex Therapeutics Ltd (ENLV)?
As of 2026Q1, 44 institutions hold shares of Enlivex Therapeutics Ltd, with a combined market value of approximately 2.13M, accounting for 0.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1519291.00.